Cited by 262Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.

Dysregulation of the mTOR Pathway Mediates Impairment of Synaptic Plasticity in a Mouse Model of Alzheimer's Disease

Open access

Abstract

BACKGROUND: The mammalian target of rapamycin (mTOR) is an evolutionarily conserved Ser/Thr protein kinase that plays a pivotal role in multiple fundamental biological processes, including synaptic plasticity. We explored the relationship between the mTOR pathway and β-amyloid (Aβ)-induced synaptic dysfunction, which is considered to be critical in the pathogenesis of Alzheimer's disease (AD). METHODOLOGY/PRINCIPAL FINDINGS: We provide evidence that inhibition of mTOR signaling correlates with impairment in synaptic plasticity in hippocampal slices from an AD mouse model and in wild-type slices exposed to exogenous Aβ1-42. Importantly, by up-regulating mTOR signaling, glycogen synthase kinase 3 (GSK3) inhibitors rescued LTP in the AD mouse model, and genetic deletion of FK506-binding protein 12 (FKBP12) prevented Aβ-induced impairment in long-term potentiation (LTP). In addition, confocal microscopy demonstrated co-localization of intraneuronal Aβ42 with mTOR. CONCLUSIONS/SIGNIFICANCE: These data support the notion that the mTOR pathway modulates Aβ-related synaptic dysfunction in AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0012845

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 mTOR signaling is impaired in an AD mouse model. (A) Western blot of acute hippocampal slices from 3–4-month-old Tg2576 mice showed decreased levels of phospho-p70S6K (Thr389), phospho-4E-BP (Thr37/46) and PSD-95 compared to wild-type (WT) slices. n = 9. *p<0.05. (B) Western blot on cultured primary neurons at 12 DIV showed decreased levels of phospho-p70S6K, phospho-4E-BP and PSD-95 in Tg2576 compared WT neurons. n = 4. *p<0.05. (C and D) Immuno-fluorescence confocal microscopy for phospho-p70S6K in the CA1 region of hippocampal slices (C) and cultured primary neurons at 12 DIV (D) showed reduced immuno-staining in Tg2576 compared to WT mice. Representative images are shown from three experiments. Scale bar, 75 µm. (E) In contrast to 3 and 9 month-old mice, reduced phospho-p70S6K was no longer evident of brains from aged (21–month-old) Tg2576 compared to WT mice. n = 8 for 3-month-old; n = 4 for 9-month-old; n = 4 for 21–month-old. *p<0.05.
Figure 1 mTOR signaling is impaired in an AD mouse model. (A) Western blot of acute hippocampal slices from 3–4-month-old Tg2576 mice showed decreased levels of phospho-p70S6K (Thr389), phospho-4E-BP (Thr37/46) and PSD-95 compared to wild-type (WT) slices. n = 9. *p<0.05. (B) Western blot on cultured primary neurons at 12 DIV showed decreased levels of phospho-p70S6K, phospho-4E-BP and PSD-95 in Tg2576 compared WT neurons. n = 4. *p<0.05. (C and D) Immuno-fluorescence confocal microscopy for phospho-p70S6K in the CA1 region of hippocampal slices (C) and cultured primary neurons at 12 DIV (D) showed reduced immuno-staining in Tg2576 compared to WT mice. Representative images are shown from three experiments. Scale bar, 75 µm. (E) In contrast to 3 and 9 month-old mice, reduced phospho-p70S6K was no longer evident of brains from aged (21–month-old) Tg2576 compared to WT mice. n = 8 for 3-month-old; n = 4 for 9-month-old; n = 4 for 21–month-old. *p<0.05.CC BY · PubMed Central
Figure 2 mTOR signaling dysfunction correlates with synaptic plasticity impairment in an AD mouse model. (A) Treatment of slices with forskolin (FSK, 50 µM, 60 min) induced phosphorylation of p70S6K in WT (n = 10) but not Tg2576 mice (n = 11). Values of densitometry from drug-treated slices are normalized to their vehicle control. *p<0.05. (B) Treatment of slices with 3,5 dihydroxyphenylglycine (DHPG, 50 µM, 60 min) induced phosphorylation of p70S6K in WT (n = 9) but not Tg2576 mice (n = 6). Values of densitometry from drug-treated slices are normalized to their vehicle control. *p<0.05. (C) High frequency stimulation (HFS) induced normal LTP in slices from 3–4-month-old WT mice (open circles), but only decremental LTP in Tg2576 mice (triangles). Pretreatment of slices with rapamycin (Rapa, 1 µM, 30 min) blocked LTP induced in WT mice (dark gray circles). n = 4 for WT and Tg; n = 6 for Rapa treated WT. Rapamycin was present throughout the recording. Scale bar, 1 mV/20 ms. The inset traces show superimposed sample EPSPs recorded during the baseline period (black) and 60 min after HFS (red). (D) Treatment of slices with Rapa (1 µM, 120 min) reduced levels of PSD-95 in WT but not Tg2576 mice. n = 5. *p<0.05.
Figure 2 mTOR signaling dysfunction correlates with synaptic plasticity impairment in an AD mouse model. (A) Treatment of slices with forskolin (FSK, 50 µM, 60 min) induced phosphorylation of p70S6K in WT (n = 10) but not Tg2576 mice (n = 11). Values of densitometry from drug-treated slices are normalized to their vehicle control. *p<0.05. (B) Treatment of slices with 3,5 dihydroxyphenylglycine (DHPG, 50 µM, 60 min) induced phosphorylation of p70S6K in WT (n = 9) but not Tg2576 mice (n = 6). Values of densitometry from drug-treated slices are normalized to their vehicle control. *p<0.05. (C) High frequency stimulation (HFS) induced normal LTP in slices from 3–4-month-old WT mice (open circles), but only decremental LTP in Tg2576 mice (triangles). Pretreatment of slices with rapamycin (Rapa, 1 µM, 30 min) blocked LTP induced in WT mice (dark gray circles). n = 4 for WT and Tg; n = 6 for Rapa treated WT. Rapamycin was present throughout the recording. Scale bar, 1 mV/20 ms. The inset traces show superimposed sample EPSPs recorded during the baseline period (black) and 60 min after HFS (red). (D) Treatment of slices with Rapa (1 µM, 120 min) reduced levels of PSD-95 in WT but not Tg2576 mice. n = 5. *p<0.05.CC BY · PubMed Central
Figure 3 Up-regulation of the mTOR pathway via GSK3 inhibition rescues LTP impairment in Tg2576 mice. (A) Compared to the LTP induced in hippocampal slices of WT mice (filled circles, n = 4), high frequency stimulation (HFS) induced normal LTP in slices from Tg2576 mice treated with LiCl (10 mM, open circles, n = 5), which was inhibited by 30 min of rapamycin (Rapa; 1 µM) pretreatment (gray triangles, n = 4). LiCl or rapamycin was present throughout the recording. (B) Similarly, treatment of slices from Tg2576 mice with kenpaullone (Ken, 5 µM, dark gray circles) prevented the impaired HFS induced LTP seen in untreated Tg2576 slices; the protection in LTP induction in Tg2576 slices by kenpaullone was inhibited by 30 min of rapamycin (1 µM) pretreatment (open circles). n = 3. Kenpaullone or rapamycin was present throughout the recording. (C) The decreased levels of phospho-p70S6K in hippocampal slices from Tg2576 compared to WT (control) mice was prevented by treatment with either Ken (5 µM) or LiCl (10 mM) for 60 min. n = 8. *p<0.05.
Figure 3 Up-regulation of the mTOR pathway via GSK3 inhibition rescues LTP impairment in Tg2576 mice. (A) Compared to the LTP induced in hippocampal slices of WT mice (filled circles, n = 4), high frequency stimulation (HFS) induced normal LTP in slices from Tg2576 mice treated with LiCl (10 mM, open circles, n = 5), which was inhibited by 30 min of rapamycin (Rapa; 1 µM) pretreatment (gray triangles, n = 4). LiCl or rapamycin was present throughout the recording. (B) Similarly, treatment of slices from Tg2576 mice with kenpaullone (Ken, 5 µM, dark gray circles) prevented the impaired HFS induced LTP seen in untreated Tg2576 slices; the protection in LTP induction in Tg2576 slices by kenpaullone was inhibited by 30 min of rapamycin (1 µM) pretreatment (open circles). n = 3. Kenpaullone or rapamycin was present throughout the recording. (C) The decreased levels of phospho-p70S6K in hippocampal slices from Tg2576 compared to WT (control) mice was prevented by treatment with either Ken (5 µM) or LiCl (10 mM) for 60 min. n = 8. *p<0.05.CC BY · PubMed Central
Figure 4 Inhibition of mTOR signaling and LTP by extracellular Aβ1-42 is prevented in FKBP12 cKO mice. (A) Treatment of slices from WT mice with exogenous Aβ1-42 (100 nM, 60 min) reduced levels of phospho-p70S6K, phospho-4E-BP, and PSD-95 compared to untreated WT slices (controls). n = 4. *p<0.05. Representative Western blot from three experiments after direct loading of the Aβ1-42 preparation (far right of the panel) showed mostly Aβ1-42 monomers, and also significant amounts of dimers and trimers. (B) LTP induced by HFS in WT mice (controls; red, n = 8) was blocked by treatment with Aβ1-42 (100 nM, blue, n = 7). In contrast, LTP was sustained in the presence of Aβ1-42 (100 nM, green) in FKBP cKO mice (n = 8). Aβ1-42 was present throughout the recording. (C) Inhibitory effects of Aβ1-42 on phospho-p70S6K were blunted in FKBP12 cKO mice. n = 5. *p<0.05. Slices were treated with Aβ1-42 for 60 min. (D) Slices from both FKBP12 cKO and WT mice treated with Aβ1-42 (60 min) exhibited normal PPF compared to the WT control. The percent facilitation, determined by the ratio of the second fEPSP to the first fEPSP (interpulse interval = 50 ms), together with representative fEPSP traces are shown. n = 5 for WT; n = 6 for WT treated with Aβ; n = 8 for FKBP12 cKO. Scale bar, 0.5 mV/25 ms.
Figure 4 Inhibition of mTOR signaling and LTP by extracellular Aβ1-42 is prevented in FKBP12 cKO mice. (A) Treatment of slices from WT mice with exogenous Aβ1-42 (100 nM, 60 min) reduced levels of phospho-p70S6K, phospho-4E-BP, and PSD-95 compared to untreated WT slices (controls). n = 4. *p<0.05. Representative Western blot from three experiments after direct loading of the Aβ1-42 preparation (far right of the panel) showed mostly Aβ1-42 monomers, and also significant amounts of dimers and trimers. (B) LTP induced by HFS in WT mice (controls; red, n = 8) was blocked by treatment with Aβ1-42 (100 nM, blue, n = 7). In contrast, LTP was sustained in the presence of Aβ1-42 (100 nM, green) in FKBP cKO mice (n = 8). Aβ1-42 was present throughout the recording. (C) Inhibitory effects of Aβ1-42 on phospho-p70S6K were blunted in FKBP12 cKO mice. n = 5. *p<0.05. Slices were treated with Aβ1-42 for 60 min. (D) Slices from both FKBP12 cKO and WT mice treated with Aβ1-42 (60 min) exhibited normal PPF compared to the WT control. The percent facilitation, determined by the ratio of the second fEPSP to the first fEPSP (interpulse interval = 50 ms), together with representative fEPSP traces are shown. n = 5 for WT; n = 6 for WT treated with Aβ; n = 8 for FKBP12 cKO. Scale bar, 0.5 mV/25 ms.CC BY · PubMed Central
Figure 5 Cellular co-localization of intraneuronal Aβ and components of the mTOR pathway in Tg2576 neurons. (A and B) Immuno-fluorescence confocal microscopy of Aβ42 with either mTOR (A) or p70S6K (B) in Tg2576 neurons at 12 DIV. Note the punctate co-localization of intraneuronal Aβ42 with mTOR and p70S6K. Scale bar, 50 µm. (C) Aβ1-42 (100 nM, 60 min) treatment failed to induce inhibition of p70S6K phosphorylation and to reduce PSD-95 levels in slices from APP KO compared to WT (control) mice. n = 9. *p<0.05.
Figure 5 Cellular co-localization of intraneuronal Aβ and components of the mTOR pathway in Tg2576 neurons. (A and B) Immuno-fluorescence confocal microscopy of Aβ42 with either mTOR (A) or p70S6K (B) in Tg2576 neurons at 12 DIV. Note the punctate co-localization of intraneuronal Aβ42 with mTOR and p70S6K. Scale bar, 50 µm. (C) Aβ1-42 (100 nM, 60 min) treatment failed to induce inhibition of p70S6K phosphorylation and to reduce PSD-95 levels in slices from APP KO compared to WT (control) mice. n = 9. *p<0.05.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

Sorted by citations

See all 262

Metadata

Authors
Ma, T., Hoeffer, C. A., Capetillo-Zarate, E., Yu, F., Wong, H., Lin, M. T., Tampellini, D., Klann, E., Blitzer, R. D., & Gouras, G. K.
Affiliations
  • Weill Cornell Medicine (US)
  • New York University (US)
  • Icahn School of Medicine at Mount Sinai (US)
Corresponding author
Gouras, Gunnar K.
Venue
PLoS ONE
Published
2010-09-20
Volume
5
Issue
9
Pages
e12845
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2071279551
Cited by
262
References
52
Citations by year
2026: 9 · 2025: 12 · 2024: 7 · 2023: 13 · 2022: 13 · 2021: 20 · 2020: 26 · 2019: 10 · 2018: 11 · 2017: 14 · 2016: 18 · 2015: 17 · 2014: 30 · 2013: 23 · 2012: 22
FWCI
13.22
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Communities in ADDI (University of the Basque Country) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Hispana (submittedVersion, cc-by)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • National Institutes of Health (N S03400 7, AG‐09464, AG28174)
  • National Institute on Aging (R01AG027140, AG09464, R01AG020729, K02AG028174, AG28174, AG027140, P01AG009464)
  • National Institute of General Medical Sciences (R01GM054508, GM-054508)
  • National Institute of Neurological Disorders and Stroke (R37NS034007, R01NS034007, R29NS034007, NS-034007)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
mTOR signaling, Alzheimer's disease, synaptic plasticity, amyloid-beta, amyloid-beta 42, long-term potentiation, glycogen synthase kinase-3, GSK-3 inhibitors, FKBP12, hippocampus, synaptic dysfunction, intraneuronal amyloid-beta
MeSH terms
Alzheimer Disease, Animals, Disease Models, Animal, Hippocampus, Humans, Mice, Inbred C57BL, Neuronal Plasticity, Peptide Fragments, Synapses, Signal Transduction, Amyloid beta-Peptides, Long-Term Potentiation, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review